ProstaGene Overview

  • Year Founded
  • 2010

Year Founded

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $27M

ProstaGene General Information

Description

Developer of a diagnostic test designed to distinguish benign from malignant prostate cancer. The company's prognostic test technology defines a group of patients with poor outcomes based on a signature of gene expression in the patient's prostate tumor and it also offers a platform for preclinical testing of therapies for metastatic prostate cancer, enabling patients to early detect and cure cancers.

Contact Information

Website
www.prostagene.com
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 100 Lancaster Avenue
  • Room 133
  • Wynnewood, PA 19096
  • United States
Primary Industry
Biotechnology
Other Industries
Other Healthcare Technology Systems
Acquirer
Cytodyn
Vertical(s)
TMT, Life Sciences, Oncology
Corporate Office
  • 100 Lancaster Avenue
  • Room 133
  • Wynnewood, PA 19096
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

ProstaGene Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Merger/Acquisition 16-Nov-2018 $27M Completed Generating Revenue
3. Accelerator/Incubator Completed Generating Revenue
2. Later Stage VC 17-Apr-2016 $400K $1.23M Completed Generating Revenue
1. Seed Round 19-May-2015 $825K $825K Completed Generating Revenue
To view ProstaGene’s complete valuation and funding history, request access »

ProstaGene Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a diagnostic test designed to distinguish benign from malignant prostate cancer. The company's prognostic t
Biotechnology
Wynnewood, PA

McLean, VA
 

Birmingham, AL
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

ProstaGene Competitors (40)

One of ProstaGene’s 40 competitors is Perthera, a Venture Capital-Backed company based in McLean, VA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Perthera Venture Capital-Backed McLean, VA
PNP Therapeutics Formerly VC-backed Birmingham, AL
Adaptive Biotechnologies Formerly VC-backed Seattle, WA
Allogene Therapeutics Formerly VC-backed South San Francisco, CA
Affini-T Venture Capital-Backed Watertown, MA
You’re viewing 5 of 40 competitors. Get the full list »

ProstaGene Patents

  • 6

    Total Documents Applications and Grants

  • Total Patents Families

  • Granted

  • 1

    Pending

  • Expiring in next 12 mo

ProstaGene Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-2861302-A4 Using modulators of ccr5 for treating cancer Inactive 14-May-2012
EP-2861302-A1 Using modulators of ccr5 for treating cancer Inactive 14-May-2012
AU-2013262977-A1 Using modulators of ccr5 for treating cancer Inactive 14-May-2012
AU-2018201516-A1 Using modulators of ccr5 for treating cancer Inactive 14-May-2012
AU-2020200083-A1 Using modulators of ccr5 for treating cancer Inactive 14-May-2012 A61K31/506
To view ProstaGene’s complete patent history, request access »

ProstaGene Former Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds
Jefferson Accelerator Zone Accelerator/Incubator
Angel (individual) Minority
Thomas Jefferson University University Minority
To view ProstaGene’s complete investors history, request access »

Ready to get started?

Request a free trial

ProstaGene FAQs

  • When was ProstaGene founded?

    ProstaGene was founded in 2010.

  • Where is ProstaGene headquartered?

    ProstaGene is headquartered in Wynnewood, PA.

  • What industry is ProstaGene in?

    ProstaGene’s primary industry is Biotechnology.

  • Is ProstaGene a private or public company?

    ProstaGene is a Private company.

  • What is the current valuation of ProstaGene?

    The current valuation of ProstaGene is .

  • What is ProstaGene’s current revenue?

    The current revenue for ProstaGene is .

  • How much funding has ProstaGene raised over time?

    ProstaGene has raised $1.23M.

  • Who are ProstaGene’s investors?

    Jefferson Accelerator Zone, , and Thomas Jefferson University have invested in ProstaGene.

  • Who are ProstaGene’s competitors?

    Perthera, PNP Therapeutics, Adaptive Biotechnologies, Allogene Therapeutics, and Affini-T are some of the 40 competitors of ProstaGene.

  • When was ProstaGene acquired?

    ProstaGene was acquired on 16-Nov-2018.

  • Who acquired ProstaGene?

    ProstaGene was acquired by Cytodyn.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »